Biomerica is still a financing story masquerading as a turnaround. The late-August private placement brings in $2.23 million, but it does so by issuing 1,393,705 shares at $1.60 and adding roughly 30% to the pre-deal share count. That is a material transfer of future upside to new capital before the operating business has earned it. With the FY2026 10-K still prepared on a going-concern basis, survival and dilution remain the investable thesis—not a demonstrated recovery.
The TickerSpark Score reinforces the gap between a superficially attractive valuation and a weak business. Biomerica's overall TickerSpark Score is 56, but its Profitability sub-score is only 20, against an 85 Valuation sub-score. The 1.49x price-to-sales multiple may look restrained, yet a sales multiple is not compelling when revenue is contracting and earnings remain negative; the trailing P/E is -2.00. Cheap-looking valuation metrics do not remove the need for another raise when the company has not demonstrated self-funding operations.
Biomerica also has real commercialization milestones that could eventually invalidate the bear thesis. The company secured Great Britain MHRA registration for hp+detect, received a first commercial order from a major European laboratory chain, launched inFoods IBS in Canada, and gained a Medicare pathway that includes a $300 national payment rate and individual-claim review. Those developments create a credible route to monetization. The problem is timing and proof: for the nine months ended February 28, revenue was $3.58 million versus $4.56 million a year earlier, alongside a $2.63 million net loss. The milestones are promising, but they have not yet displaced the financing narrative in reported results.
The trigger to change our view is not another product announcement or another insider purchase. It is sustained revenue growth from inFoods IBS and hp+detect, evidence that reimbursement is converting into claims and orders, and a visible reduction in the need for external capital. Until those conditions appear in the financial statements, position sizing belongs in the speculative bucket, if anywhere. Biomerica's $2.23 million raise extends the runway, but the runway warning remains the story.
Our take, not advice. This is opinion commentary — informational only, not personalized investment recommendations. Markets carry risk. Do your own research and consider your own situation before any trade.
